Chugai Pharmaceutical Co., Ltd. (CHGCY)

OTCMKTS: CHGCY · Delayed Price · USD
+0.06 (0.52%)
Mar 28, 2023, 10:52 AM EDT - Market open
Market Cap 40.85B
Revenue (ttm) 8.62B
Net Income (ttm) 2.80B
Shares Out 3.31B
EPS (ttm) 0.85
PE Ratio 14.37
Forward PE 18.05
Dividend $0.60 (4.79%)
Ex-Dividend Date Dec 29, 2022
Volume 35,000
Open 12.68
Previous Close 12.41
Day's Range 12.25 - 12.68
52-Week Range 10.99 - 17.49
Beta 0.51
Analysts Buy
Price Target 15.65 (+24.34%)
Earnings Date n/a


Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product... [Read more]

Sector Healthcare
Founded 1925
Employees 7,664
Stock Exchange OTCMKTS
Ticker Symbol CHGCY
Full Company Profile

Financial Performance

In 2021, CHGCY's revenue was 999.76 billion, an increase of 27.04% compared to the previous year's 786.95 billion. Earnings were 303.00 billion, an increase of 41.10%.

Financial numbers in JPY Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for CHGCY stock is "Buy." The 12-month stock price forecast is $15.65, which is an increase of 24.34% from the latest price.

Price Target
(24.34% upside)
Analyst Consensus: Buy
Stock Forecasts


There is no news available yet.